Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
10 2021
Historique:
received: 12 05 2021
revised: 28 06 2021
accepted: 09 07 2021
pubmed: 21 7 2021
medline: 15 12 2021
entrez: 20 7 2021
Statut: ppublish

Résumé

In recent years, 5-pyrazolyl-ureas have mostly been known for their attractive poly-pharmacological outline and, in particular, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl) ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a capable anti-angiogenic compound. This paper examines its interactome by functional proteomics using a label-free mass spectrometry based platform, coupling Drug Affinity Responsive Target Stability and targeted Limited Proteolysis-Multiple Reaction Monitoring. Calreticulin has been recognized as the GeGe-3 principal target and this evidence has been supported by immunoblotting and in silico molecular docking. Furthermore, cell studies have shown that GeGe-3 lowers cell calcium mobilization, cytoskeleton organization and focal adhesion kinase expression, thus linking its biological potential to calreticulin binding and, ultimately, shedding light on the reasonable action mechanism of this molecule as an anti-angiogenic factor.

Identifiants

pubmed: 34284173
pii: S0045-2068(21)00545-9
doi: 10.1016/j.bioorg.2021.105168
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Calreticulin 0
Proteome 0
Pyrazoles 0
pyrazole 3QD5KJZ7ZJ
Ionomycin 56092-81-0
Urea 8W8T17847W
Focal Adhesion Kinase 1 EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105168

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Elva Morretta (E)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Salerno, Italy. Electronic address: emorretta@unisa.it.

Raffaella Belvedere (R)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Salerno, Italy. Electronic address: rbelvedere@unisa.it.

Antonello Petrella (A)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Salerno, Italy. Electronic address: apetrella@unisa.it.

Andrea Spallarossa (A)

Department of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy. Electronic address: andrea.spallarossa@unige.it.

Federica Rapetti (F)

Department of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy. Electronic address: federica.rapetti@edu.unige.it.

Olga Bruno (O)

Department of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy. Electronic address: obruno@unige.it.

Chiara Brullo (C)

Department of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy. Electronic address: brullo@difar.unige.it.

Maria Chiara Monti (MC)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Salerno, Italy. Electronic address: mcmonti@unisa.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH